Neostigmine Bromide from Alliance Pharmaceuticals

We have received communication regarding Neostigmine Bromide from Alliance Pharmaceuticals. If this situation affects you, our advice would be for you to contact your neurologist for an alternate medication prescription, or to contact your GP to get a referral to neurology to obtain an alternate medication.

Alliance Pharmaceuticals Ltd will be discontinuing the supply of Neostigmine Bromide Tablets 15mg (stock expiry end October 2020).

Neostigmine bromide is indicated for myasthenia gravis, paralytic ileus and post-operative urinary retention of which there are several alternative treatment options including pyridostigmine bromide.

The decision to discontinue supply of Neostigmine has been a difficult one, but has been made due to low levels of demand and increased alternative therapy options. As a result, the production of this medicine is no longer feasible, with final stocks due to expire in October 2020.

We appreciate this news could impact patients and hope that, by proactively communicating our intentions, impacted person(s) will have sufficient time to discuss this with their prescribing healthcare physician and find a suitable, alternative treatment option. We trust this information to have been of interest.

Drugs to avoid